Expanding Life Science Footprint, Agilent Buying Halo, BioSystem's Assets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today announced two deals that are expected to grow its footprint in the life science space.

The company said it has acquired next-generation sequencing sample preparation firm Halo Genomics and has signed a definitive agreement to acquire the assets of drug development sample prep firm BioSystem Development.

Financial terms of the two deals were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.